Literature DB >> 27016292

RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases.

Kristoffer Watten Brudvik1, Yoshihiro Mise1, Michael Hsiang Chung1, Yun Shin Chun1, Scott E Kopetz2, Guillaume Passot1, Claudius Conrad1, Dipen M Maru3, Thomas A Aloia1, Jean-Nicolas Vauthey4.   

Abstract

BACKGROUND: In patients undergoing resection of colorectal liver metastases (CLM), resection margin status is a significant predictor of survival, particularly in patients with suboptimal response to preoperative therapy. RAS mutations have been linked to more invasive and migratory tumor biology and poor response to modern chemotherapy.
OBJECTIVE: The aim of this study was to evaluate the relationship between RAS mutation and resection margin status in patients undergoing resection of CLM.
METHODS: Patients who underwent curative resection of CLM from 2005 to 2013 with known RAS mutation status were identified from a prospectively maintained database. A positive margin was defined as tumor cells <1 mm from the parenchymal transection line.
RESULTS: The study included 633 patients, of whom 229 (36.2 %) had mutant RAS. The positive margin rate was 11.4 % (26/229) for mutant RAS and 5.4 % (22/404) for wild-type RAS (p = 0.007). In multivariate analysis, the only factors associated with a positive margin were RAS mutation (hazard ratio [HR] 2.439; p = 0.005) and carcinoembryonic antigen level 4.5 ng/mL or greater (HR 2.060; p = 0.026). Among patients presenting with liver-first recurrence during follow-up, those with mutant RAS had narrower margins at initial CLM resection (median 4 mm vs. 7 mm; p = 0.031). A positive margin (HR 3.360; p < 0.001) and RAS mutation (HR 1.629; p = 0.044) were independently associated with worse overall survival.
CONCLUSION: RAS mutations are associated with positive margins in patients undergoing resection of CLM. Tumors with RAS mutation should prompt careful efforts to achieve negative resection margins.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27016292      PMCID: PMC5527830          DOI: 10.1245/s10434-016-5187-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  44 in total

1.  Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations.

Authors:  J N Vauthey; A Chaoui; K A Do; M M Bilimoria; M J Fenstermacher; C Charnsangavej; M Hicks; G Alsfasser; G Lauwers; I F Hawkins; J Caridi
Journal:  Surgery       Date:  2000-05       Impact factor: 3.982

2.  The impact of margins on outcome after hepatic resection for colorectal metastasis.

Authors:  Chandrakanth Are; Mithat Gonen; Kathleen Zazzali; Ronald P Dematteo; William R Jarnagin; Yuman Fong; Leslie H Blumgart; Michael D'Angelica
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

3.  RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.

Authors:  Jean-Nicolas Vauthey; Giuseppe Zimmitti; Scott E Kopetz; Junichi Shindoh; Su S Chen; Andreas Andreou; Steven A Curley; Thomas A Aloia; Dipen M Maru
Journal:  Ann Surg       Date:  2013-10       Impact factor: 12.969

4.  Tumor growth pattern as predictor of colorectal liver metastasis recurrence.

Authors:  Rafael S Pinheiro; Paulo Herman; Renato M Lupinacci; Quirino Lai; Evandro S Mello; Fabricio F Coelho; Marcos V Perini; Vincenzo Pugliese; Wellington Andraus; Ivan Cecconello; Luiz Carneiro D'Albuquerque
Journal:  Am J Surg       Date:  2013-10-07       Impact factor: 2.565

5.  Effect of subcentimeter nonpositive resection margin on hepatic recurrence in patients undergoing hepatectomy for colorectal liver metastases. Evidences from 663 liver resections.

Authors:  J Figueras; F Burdio; E Ramos; J Torras; L Llado; S Lopez-Ben; A Codina-Barreras; S Mojal
Journal:  Ann Oncol       Date:  2007-04-13       Impact factor: 32.976

6.  Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence.

Authors:  K S Hughes; R Simon; S Songhorabodi; M A Adson; D M Ilstrup; J G Fortner; B J Maclean; J H Foster; J M Daly; D Fitzherbert
Journal:  Surgery       Date:  1986-08       Impact factor: 3.982

7.  Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate?

Authors:  Eran Sadot; Bas Groot Koerkamp; Julie N Leal; Jinru Shia; Mithat Gonen; Peter J Allen; Ronald P DeMatteo; T Peter Kingham; Nancy Kemeny; Leslie H Blumgart; William R Jarnagin; Michael I DʼAngelica
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

8.  Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.

Authors:  Georgios Karagkounis; Michael S Torbenson; Hubert D Daniel; Nilofer S Azad; Luis A Diaz; Ross C Donehower; Kenzo Hirose; Nita Ahuja; Timothy M Pawlik; Michael A Choti
Journal:  Cancer       Date:  2013-09-19       Impact factor: 6.860

9.  One-millimeter cancer-free margin is curative for colorectal liver metastases: a propensity score case-match approach.

Authors:  Zaed Z R Hamady; J Peter A Lodge; Fenella K Welsh; Giles J Toogood; Alan White; Timothy John; Myrddin Rees
Journal:  Ann Surg       Date:  2014-03       Impact factor: 12.969

10.  Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival.

Authors:  Jon-Helge Angelsen; Arild Horn; Geir Egil Eide; Asgaut Viste
Journal:  World J Surg Oncol       Date:  2014-04-27       Impact factor: 2.754

View more
  37 in total

Review 1.  SSAT State-of-the-Art Conference: New Frontiers in Liver Surgery.

Authors:  Guido Torzilli; Masato Nagino; Ching-Wei D Tzeng; T Peter Kingham; Olusegun I Alatise; Omobolaji O Ayandipo; Suguru Yamashita; Amanda K Arrington; Joseph Kim; Yun Shin Chun; Jean-Nicolas Vauthey
Journal:  J Gastrointest Surg       Date:  2016-08-01       Impact factor: 3.452

2.  Prediction of KRAS, NRAS and BRAF status in colorectal cancer patients with liver metastasis using a deep artificial neural network based on radiomics and semantic features.

Authors:  Ruichuan Shi; Weixing Chen; Bowen Yang; Jinglei Qu; Yu Cheng; Zhitu Zhu; Yu Gao; Qian Wang; Yunpeng Liu; Zhi Li; Xiujuan Qu
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

3.  Surgery: KRAS mutations and hepatic recurrence after treatment of colorectal liver metastases.

Authors:  Kristoffer Watten Brudvik; Jean-Nicolas Vauthey
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

Review 4.  Interventional Treatment of Hepatic Metastases from Colorectal Cancer.

Authors:  Patrick D Sutphin; Suvranu Ganguli
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

Review 5.  Gene mutation and surgical technique: Suggestion or more?

Authors:  Yoshikuni Kawaguchi; Heather A Lillemoe; Jean-Nicolas Vauthey
Journal:  Surg Oncol       Date:  2019-07-18       Impact factor: 3.279

6.  Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status.

Authors:  B C Odisio; S Yamashita; S Y Huang; S Harmoush; S E Kopetz; K Ahrar; Y Shin Chun; C Conrad; T A Aloia; S Gupta; M E Hicks; J-N Vauthey
Journal:  Br J Surg       Date:  2017-02-27       Impact factor: 6.939

7.  Histopathological growth patterns and positive margins after resection of colorectal liver metastases.

Authors:  Pieter M H Nierop; Diederik J Höppener; Eric P van der Stok; Boris Galjart; Florian E Buisman; Vinod P Balachandran; William R Jarnagin; T Peter Kingham; Peter J Allen; Jinru Shia; Peter B Vermeulen; Bas Groot Koerkamp; Dirk J Grünhagen; Cornelis Verhoef; Michael I D'Angelica
Journal:  HPB (Oxford)       Date:  2019-11-15       Impact factor: 3.647

8.  The Prognostic Impact of KRAS Mutation in Patients Having Curative Resection of Synchronous Colorectal Liver Metastases.

Authors:  Paolo Goffredo; Alan F Utria; Anna C Beck; Yun Shin Chun; James R Howe; Ronald J Weigel; Jean-Nicolas Vauthey; Imran Hassan
Journal:  J Gastrointest Surg       Date:  2018-10-01       Impact factor: 3.452

9.  RAS Mutation Is Associated with Decreased Survival in Patients Undergoing Repeat Hepatectomy for Colorectal Liver Metastases.

Authors:  Jason W Denbo; Suguru Yamashita; Guillaume Passot; Michael Egger; Yun S Chun; Scott E Kopetz; Dipen Maru; Kristoffer Watten Brudvik; Steven H Wei; Claudius Conrad; Jean-Nicolas Vauthey; Thomas A Aloia
Journal:  J Gastrointest Surg       Date:  2016-06-22       Impact factor: 3.452

Review 10.  The Landmark Series: Randomized Control Trials Examining Perioperative Chemotherapy and Postoperative Adjuvant Chemotherapy for Resectable Colorectal Liver Metastasis.

Authors:  Yoshikuni Kawaguchi; Jean-Nicolas Vauthey
Journal:  Ann Surg Oncol       Date:  2020-08-14       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.